Volta Medical SAS
18.04.2024 - 14:00:10Volta Medical Announces Late-Breaking TAILORED-AF Randomized Clinical Trial Results at Heart Rhythm 2024 in Boston, MA, USA
Volta Medical SAS / Key word(s): Study 18.04.2024 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Late-Breaking Randomized Clinical Trial Data to be presented by Professor Isabel Deisenhofer, German Heart Center Munich Department of Electrophysiology Demonstration of Volta AF-Xplorer™ at Heart Rhythm Society (HRS) 2024, May 16-19 Dr. Andrea Natale, a world recognized leader in the field of electrophysiology, to moderate Rhythm Theater Marseille (France), April 18, 2024 – Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologists in assessing complex cardiac arrhythmias such as atrial fibrillation (AF), today announced presentations to be made at the Heart Rhythm Society 2024 meeting in Boston, MA, USA, from May 16 to 19. In-person attendance and live online participation in a hybrid format will be available. Professor Isabel Deisenhofer, German Heart Center Munich Department of Electrophysiology will present late breaking data from the Volta TAILORED-AF clinical trial. Additionally, Volta will host a demonstration of Volta AF-Xplorer™ and a Rhythm Theater featuring a panel of experts in the field moderated by Dr. Andrea Natale, a leading cardiac electrophysiologist at the Texas Cardiac Arrhythmia Institute at St. David's Medical Center in Austin, TX, USA. Summary of Presentations:
Volta Medical is a health technology company developing artificial intelligence software solutions to assist cardiac electrophysiologists during arrhythmia treatment procedures to improve clinical outcomes for patients. Founded by three physicians and a data scientist in 2016 in Marseille, Volta’s overarching goal is to improve cardiac arrhythmia management by developing state-of-the-art, data-driven medical devices trained on large databases of procedural data. The company’s solution, AF-Xplorer™, is a digital AI companion device and algorithm to assist cardiologists with real-time identification of specific abnormal electrograms, known as dispersed EGMs. AF-Xplorer™ is CE marked and FDA cleared. For more information, visit the company’s website at www.volta-medical.com. Media Contact Jeff Martin, SVP of Global Marketing Volta Medical jeffrey.martin@volta-medical.com European Media Contact Brittney Sojeva MC Services AG Volta-medical@mc-services.eu References ____________________ https://www.heart.org/en/health-topics/atrial-fibrillation [last accessed June 9, 2023] Colilla S, Crow A, Petku W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013; 112:1142–1147. DOI: 10.1016/j.amjcard.2013.05.063 https://kompetenznetz-vorhofflimmern.de/en [last accessed June 9, 2023] 18.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com |
Language: | English |
Company: | Volta Medical SAS |
65 Avenue Jules Cantini | |
13006 Marseille | |
France | |
E-mail: | contact@volta-medical.com |
Internet: | www.volta-medical.com |
EQS News ID: | 1883195 |
End of News | EQS News Service |
|